Similar Search Results

Comparing Patient Access to Pharmaceuticals in the UK and US

Cohen, Joshua; Cairns, Catherine; Paquette, Cherie; … - In: Applied Health Economics and Health Policy 5 (2006) 3, pp. 177-187

reimbursement and pricing of approved drugs, the so-called fourth and fifth hurdles. Methods: We reviewed 38 National Institute for … approved. Thirdly, we considered whether and when each drug was recommended for reimbursement and use by NICE, and whether … conditions of reimbursement applied. Fourthly, for the subset of FDA-approved drugs, we examined formulary placement, cost …

Persistent link: https://www.econbiz.de/10005590240

New Drugs for Osteoporosis: Comparison of the Costs and Required Returns With Those of Other Drugs Intended for Long-Term Use

Edwards, Martin - In: PharmacoEconomics 15 (1999) 3, pp. 269-278

Specific regulatory guidelines dictate that developing a new drug for osteoporosis will be significantly more expensive and take at least 2 years longer in comparison with other long-term therapies developed using the International Committee on Harmonisation (ICH) general guidelines. Assuming...

Persistent link: https://www.econbiz.de/10005590530

The Selection of Data Sources For Use in Modelling Studies

Nuijten, Mark J.C. - In: PharmacoEconomics 13 (1998) 3, pp. 305-316

Economic analysis has become increasingly important in healthcare in general, and particularly with respect to pharmaceuticals. Therefore, it is vital that the methods used in such evaluations are carefully scrutinised and refined. However, guidelines contain only a limited number of...

Persistent link: https://www.econbiz.de/10005449056

Management of HIV-1 Infection in Children: Special Considerations

Brady, Michael T. - In: Disease Management and Health Outcomes 4 (1998) 2, pp. 73-91

Optimal management of human immunodeficiency virus type 1 (HIV-1)-infected children requires a commitment from the healthcare delivery system, healthcare providers, and affected families and caregivers. When adequate resources are available (as in most industrialised nations), an aggressive...

Persistent link: https://www.econbiz.de/10005448902

Herbal Remedies: Issues in Licensing and Economic Evaluation

Ashcroft, Darren M.; Li Wan Po, Alain - In: PharmacoEconomics 16 (1999) 4, pp. 321-328

In recent years, the use of alternative therapies has become widespread. In particular, there has been a resurgence in the public's demand for herbal remedies, despite a lack of high-quality evidence to support the use of many of them. Given the increasing pressures to control healthcare...

Persistent link: https://www.econbiz.de/10005405015

Should Antibacterials Be Deregulated?

Rovira, Joan; Figueras, Montserrat; Segu, Josep L. - In: PharmacoEconomics 13 (1998) 5, pp. 499-508

Deregulation of antibacterials is a recurrent topic in the debate on pharmaceutical policy. This article focuses on one aspect of pharmaceutical regulation, namely the requirement of a medical prescription for purchasing antibacterials. However, a strategy of deregulation should not only concern...

Persistent link: https://www.econbiz.de/10005449163

A 3-Dimensional View of Access to Licensed and Subsidized Medicines under Single-Payer Systems in the US, the UK, Australia and New Zealand

Ragupathy, Rajan; Aaltonen, Katri; Tordoff, June; … - In: PharmacoEconomics 30 (2012) 11, pp. 1051-1065

licensing bodies and public reimbursement agencies. The present study compares access to licensed and subsidized medicines under …

Persistent link: https://www.econbiz.de/10010579442

Threshold Analysis of Helicobacter pylori Therapy

Sonnenberg, Amnon - In: PharmacoEconomics 14 (1998) 4, pp. 423-432

Objective: Conflicting recommendations have been made on whom to treat with antibacterials to eradicate Helicobacter pylori . The present analysis aims to explain the basis of such discrepancies. Design and Setting: The decision in favour of or against antibacterial therapy in patients with...

Persistent link: https://www.econbiz.de/10005404790

Predicting Hospitalisation of Patients with Diabetes Mellitus: An Application of the Bayesian Discriminant Analysis

Bhattacharyya, Samir K. - In: PharmacoEconomics 13 (1998) 5, pp. 519-529

The objective of this study was to develop, and subsequently test, a Bayesian discrimination model for the purpose of identifying both the personal and the healthcare system characteristics predictive of hospitalisation for the treatment of patients with diabetes mellitus or commonly observed...

Persistent link: https://www.econbiz.de/10005404891

The Use of the Bootstrap Statistical Method for the Pharmacoeconomic Cost Analysis of Skewed Data

Desgagne, Alain; Castilloux, Anne-Marie; Angers, … - In: PharmacoEconomics 13 (1998) 5, pp. 487-497

In pharmacoeconomics, the comparison of the costs of 2 different drugs used for the same treatment is of great interest. The problem is especially challenging when the drugs are likely to produce costly adverse effects in a small number of patients, which is often the case. The data are then...

Persistent link: https://www.econbiz.de/10005590319